The structures of recombinant histo-aspartic protease (HAP) from malariacausing parasite Plasmodium falciparum as apoenzyme and in complex with two inhibitors, pepstatin A and KNI-10006, were solved at 2.5-, 3.3-, and 3.05-Å resolutions, respectively. In the apoenzyme crystals, HAP forms a tight dimer not seen previously in any aspartic protease. The interactions between the monomers affect the conformation of two flexible loops, the functionally important "flap" (residues 70-83) and its structural equivalent in the C-terminal domain (residues 238-245), as well as the orientation of helix 225-235. The flap is found in an open conformation in the apoenzyme. Unexpectedly, the active site of the apoenzyme contains a zinc ion tightly bound to His32 and Asp215 from one monomer and to Glu278A from the other monomer, with the coordination of Zn resembling that seen in metalloproteases. The flap is closed in the structure of the pepstatin A complex, whereas it is open in the complex with KNI-10006. Although the binding mode of pepstatin A is significantly different from that in other pepsin-like aspartic proteases, its location in the active site makes unlikely the previously proposed hypothesis that HAP is a serine protease. The binding mode of KNI-10006 is unusual compared with the binding of other inhibitors from the KNI series to aspartic proteases. The novel features of the HAP active site could facilitate design of specific inhibitors used in the development of antimalarial drugs.
Introduction
Histo-aspartic protease (HAP) is one of the 10 plasmepsins (PMs) identified in the genome of Plasmodium falciparum, the parasite responsible for the most widespread form of malaria. It is one of the 4 PMs residing in the food vacuole of the parasite that are involved in degradation of human hemoglobin, 1 making them potential targets for novel antimalarial therapy. 2 Despite its high sequence identity (60%) with other PMs (PMI, PMII, and PMIV), which are typical pepsin-like aspartic proteases, the active site of HAP contains several significant deviations from the pepsin standard. 3 In particular, Asp32 †, which together with Asp215 creates the catalytic dyad in classic aspartic proteases, is replaced by a histidine, giving this enzyme its name. In addition, substitutions are found in the functionally important flexible loop called the "flap" (residues 70-83), which changes its conformation upon ligand binding and thus participates in catalysis. These substitutions include the strictly conserved Tyr75 and the highly conserved Val/Gly76, which are replaced by Ser and Lys, respectively. Although the overall level of sequence similarity suggests that HAP should have a pepsin-like fold, the predicted details of the active-site architecture and, consequently, the mode of enzymatic activity *Corresponding author. E-mail address: alla@ncifcrf.gov. Abbreviations used: HAP, histo-aspartic protease; PM, plasmepsin; NCS, non-crystallographic symmetry; mtHAP, mature tHAP; PEG, polyethylene glycol; TLS, translation-libration-screw. † For consistency, the numbering of residues in HAP follows the system used for porcine pepsin. Gaps in the numbering correspond to residues found in pepsin but not in HAP, and insertions in HAP are designated by letters A, B, C, etc., appended to residue numbers.
have been subjects of considerable disagreement. In the model published by Andreeva et al., 4 HAP was postulated to function as a trypsin-like serine protease, with the catalytic triad consisting of Ser35, His32, and Asp215. On the other hand, Bjelic and Aqvist 5 postulated a reaction mechanism of HAP that would assign a direct catalytic role only to Asp215, whereas the role of His32 would be to provide critical ∼ 10,000-fold stabilization along the reaction path. It has become clear that experimental structural evidence is necessary to validate or disprove these predictions.
Whereas some enzymatic properties of HAP isolated from P. falciparum could be determined, the amounts of the enzyme that could be purified from the parasite 1 have not been sufficient for structural studies. Initial efforts to clone and express HAP yielded inactive enzyme only. 3 Although the specific activity of the enzyme with a fluorescent substrate optimized for PMI and PMII was comparatively low and the mode of inhibition and pH activity profile were not consistent between different purification protocols, we subsequently succeeded in producing active recombinant HAP. 6, 7 In this article, we report the crystal structures of recombinant HAP in ligand-free form and in complex with two inhibitors, pepstatin A 8 and KNI-10006. 9 The results do not directly support either of the proposed mechanisms and raise a number of questions that will require further studies.
Results and Discussion
Overall fold and structure quality Crystal structures of uncomplexed HAP and its complexes with pepstatin A and KNI-10006 (Fig. 1a) have been refined using data extending to 2.5-, 3.3-, and 3.05-Å resolutions, respectively. The fit of the final models to electron density maps is satisfactory, and the quality of the structures, as measured by such parameters as the R-factor or departure from stereochemical standards, 10 meets the acceptable criteria given the limited resolution of the diffraction data. 11, 12 The electron density maps for the inhibitors are of sufficient quality to define their configuration unambiguously (Fig. 1b) .
As predicted, 3 the overall fold of HAP follows the canon of eukaryotic aspartic proteases defined by pepsin (Fig. 2a) . Examples of typical pepsin-like proteases with known structures include mammalian enzymes, such as chymosin, renin, and cathepsin D, 13 the fungal enzyme endothiapepsin, 14 and the Plasmodium enzymes PMII 15 and PMIV. 16 These bilobal proteins are composed of two topologically similar N-and C-terminal domains, with a large substrate-binding cleft between them. The amino and carboxyl ends of the HAP chain are assembled into a characteristic six-stranded interdomain β-sheet that serves to suture the domains together. The conserved sequence DT(S)G, present in one copy in each domain and containing the catalytic aspartate residues, is the signature motif of aspartic proteases. 13 Although the two signatures are recognizable in the HAP sequence, they show unusual modifications. The catalytic aspartate of the Nterminal domain is substituted by His32, and both conserved glycines are replaced by alanines. The flap is open in the apoenzyme and is closed in the complex with pepstatin A, in a manner reminiscent of typical aspartic proteases. However, the conformation of the flap loop in the KNI-10006 complex resembles that of the apoenzyme due to an unusual binding mode of the inhibitor (see below).
The structures of the apo form and the pepstatin A complex of HAP were compared using ALIGN 17 with the structures of unliganded pepsin [Protein Data Bank (PDB) ID 4PEP] and its pepstatin A complex (PDB ID 1PSO). The pepstatin A complex of HAP was also compared with the pepstatin A complexes of PMII (PDB ID 1XDH) and PMIV (PDB ID 1LS5). The four superpositions based on the C α atoms gave rmsd values of 1.72, 1.73, 1.07, and 1.27 Å, respectively. The largest deviations are observed in the flap area, as well as for the loops containing residues 238-245 and 276-283. The superposition of the pepstatin A complexes of HAP, pepsin, PMII, and PMIV (Fig. 2b) has been used to create the structurally based sequence alignment shown in Fig. 2c .
Apoenzyme structure
The two molecules of HAP present in the tetragonal crystals of the apoenzyme form a tight dimer (Fig. 3a) involving very close contacts of their Cterminal domains, whereas the N-terminal domains point away from each other. The two monomers are related by a local 2-fold axis and can be superimposed with an rmsd of 0.32 Å between the corresponding C α atoms. Upon dimerization, the fragment that contains helix 225-235 and the following loop 238-245 is displaced from its position commonly seen in aspartic proteases. The movement of this fragment is a consequence of the mutual insertion of loop 276-283 of the second monomer into the putative active site of the first monomer.
Asojo et al. 15 reported several dimeric forms of PMs created by crystallographic symmetry and noncrystallographic symmetry (NCS). However, the type of tight non-crystallographic dimer seen in the crystals of HAP apoenzyme is unique not only among PMs but also among all known pepsin-like aspartic proteases. An unusual feature found in the crystals of unliganded HAP is the presence of a zinc ion in the active site of each monomer, interacting with His32 and Asp215. The tetrahedral coordination of Zn in monomer A is completed by Glu278A, located in the intruding loop of monomer B (and vice versa), and by a water molecule (Fig. 3b) . Two hydrophobic residues, Ile279A and Phe279B, from the same loop are packed inside a hydrophobic pocket formed by Phe109A, Ile80, Met104, Ile107, and Val120 of the first monomer. 15 On the face of it, it would appear that the observed dimeric state of HAP should be even more indicative of its relevance to function. However, as discussed below, we are not certain that this is indeed the case.
Four additional Zn ions are found on the surface of the HAP dimer. Two of them are located in equivalent positions in each monomer and are coordinated to His204 and Asp202. The third Zn ion interacts with Asp134 and His193 of monomer A and a water molecule, and the fourth one is coordinated by Glu54 and Glu57 of monomer A and by Glu57 and a water molecule from the symmetry-related monomer B. It is unlikely that these additional Zn ions play any role in the mechanism of catalysis by HAP.
Comparison between apo HAP and its pepstatin A complex
The complex of HAP with pepstatin A crystallized with one protein molecule in the asymmetric unit. Despite the overall similarity to the apoenzyme structure (rmsd values of 0.98 and 0.96 Å for the C α atoms relative to monomers A and B of apo HAP, respectively), pronounced differences are seen in the conformation of two fragments, namely the flap and the segment that contains helix 225-235 and loop 238-245 (Fig. 4) . The differences between the C α coordinates of the flap residues are in the range of 2.5-6.9 Å, with the largest shift at Lys76, a residue that is uniquely present in this location in HAP only. The whole fragment containing helix 225-235 and loop 238-245 moved in a concerted manner, with the largest deviation (19.7 Å at Val240) observed in the loop area. Several previous studies reported rigidbody movement of large fragments of the Cterminal domain of pepsin-like enzymes upon ligand binding, [19] [20] [21] but the amplitude seen in the structure of HAP is unprecedented, revealing a remarkable flexibility of this part of the structure. In the crystal structure of HAP complexed with pepstatin A, helix 225-235 is not involved in any crystal contact, whereas loop 238-245 is. The side chains of Phe238, Pro241, Phe242, and Leu244 are in contact with the hydrophobic part of the side chains of Glu278A, Asn11, Ala10, and Leu244 from a symmetry-related molecule, respectively. It is also important to note that the side chain of Leu243 is also in contact with IVA1 of pepstatin A from a symmetry-related molecule.
An important role of loop 238-245 in forming the extended active-site area and thus in contributing to specificity and functional properties of aspartic proteases has been the subject of debate for almost two decades. Structural studies of chymosin clearly indicated that specific cleavage of the bond between Phe105 and Met106 (P1-P1′) in κ-casein, responsible for the high level of milk-clotting activity of this enzyme, was assisted by electrostatic interactions between a positively charged cluster His-Pro-HisPro-His at positions P8-P4 (98-102) of the casein substrate and the negatively charged residues in loop 244-248 of chymosin (a structural equivalent of loop 238-245 in HAP). [22] [23] [24] N-terminal extension beyond the P6 position of the peptide substrates also increased the catalytic efficiency of cathepsin E and that of several members of the PM family. Loop 238-245 in PMs has a sequence pattern notably different from its counterpart in other aspartic proteases. In other PMs that are found in the digestive vacuole of P. falciparum and other Plasmodium species, the strictly hydrophobic nature of this loop is conserved ( Fig. 5a and b) . However, in PMV to PMX, which are not involved in hemoglobin degradation, the sequences of this loop are significantly different. It was proposed in several studies that, in PMs, this loop is involved in distal interactions with the substrate that enhance the enzymatic activity. 25, 26 Mutation of hydrophobic residues (Phe244) and deletion of Phe241 have resulted in impaired hemoglobin proteolysis, leading to the current hypothesis that recognition by this loop of hydrophobic patches on hemoglobin surface, distant from the cleavage site, weakens the substrate structure and thus initiates its degradation. 26, 27 The structure of the apoenzyme of HAP supports this idea, revealing a remarkable flexi- bility of this loop that would be required to play such a functional role.
The overall mode of binding of pepstatin A to HAP resembles the mode of binding of this inhibitor that was previously reported in the structures of PMII (PDB ID 1XDH) and PMIV (PDB ID 1LS5). Pepstatin A is bound in extended conformation, with the statine hydroxyl positioned between Asp215 and His32. However, binding of the C-terminal half of the inhibitor is distinctly different from that found in complexes with PMs and other pepsin-like proteases. Instead of wrapping around the flap, as observed with other enzymes, it is oriented toward loop 287-292, making extensive interactions with the residues comprising this fragment (Fig. 6a) . The flap is closed in the structure of the complex, and the Lys76 residue located at its tip interacts with the inhibitor via hydrophobic contacts with the side chain of the Sta residue at the P3′ position of pepstatin A (Fig. 6b) . The ω-ammonium group of Lys76 is linked via a hydrogen bond to the carbonyl oxygen of Ala at the P2′ position of pepstatin A. A charged residue with such a long side chain at this position in HAP (versus glycine in PMIV or valine in PMII) is unique among PMs and most other pepsinlike proteases. It seems reasonable to propose that the shift of the C-terminal half of pepstatin A may be due to the presence of an unusually large residue at the tip of the flap in HAP.
Only two other hydrogen bonds between pepstatin A and HAP are clearly identified: one is between the carbonyl oxygen of Val at the P2 position and the amide of Ser219, whereas the second one is between the amide of Sta at P1 and O γ1 of Thr218. Thus, the hydrogen-bonding interactions of pepstatin A with HAP are not as extensive as those observed in the pepstatin A complex of PMII 15 due to a different orientation of the C-terminal half of the inhibitor that prevents formation of hydrogen bonds with flap residues. The side chains of pepstatin A at both termini of the molecule are also involved in extensive hydrophobic interactions with HAP residues. The isovaleryl group at the N-terminus of the inhibitor and the side chain of Val at P3 interact with Phe111, Val12, and Leu13 in HAP. The P2 valine interacts with the methyl group of the side chain of Thr218, as well as with the side chains of Val287 and Ile289. The side chain of Sta P1 interacts with Phe109A, while Ala at the P2′ position is involved in hydrophobic interactions with Met189 and Leu291. Finally, the side chain of Glu292 helps stabilize the conformation of the C-terminus of pepstatin A.
Structure of HAP in complex with KNI-10006
KNI-10006 (Fig. 1a) is a peptidomimetic inhibitor from a series of the so-called KNI compounds. These inhibitors have been developed during the last 20 years in a program aimed at the creation of chemotherapeutic anti-HIV agents targeting the retroviral protease. 28, 29 The design of this series was based on the concept of "substrate transition-state mimicry," 30 with the central core made of an α-hydroxy-β-amino acid derivative, allophenylnorstatine, which contains a hydroxymethylcarbonyl isostere. It has been also reported that KNI compounds demonstrated effective inhibition of not only HIV-1 protease but also PMII and HTLV-1 protease. 31 Further chemical elaboration and optimization of the KNI inhibitors, supported by extensive structural and biochemical data, resulted in the synthesis of many new compounds shown to be potent inhibitors of HIV-1 and HTLV-1 proteases. 9, [32] [33] [34] [35] [36] One of them, KNI-10006, was subsequently shown to be a potent inhibitor of HAP 37 with an IC 50 of 0.69 μM and was thus chosen for the evaluation of its interaction with the enzyme. The binding mode of KNI-10006 to HAP is drastically different from that of pepstatin A (Fig. 7) , as well as from a number of other KNI inhibitors bound to various aspartic proteases. In the HAP complex, the hydroxyl group in the central part of the inhibitor points away from the catalytic residues, in contrast to its orientation in the structure of either HIV-1 protease 38 or PMIV, 15 where it is positioned between the active-site aspartates (Fig. 8a) . The predominant interactions of KNI-10006 are with the flap, and this inhibitor does not make any contact either with loop 287-292 or with several other hydrophobic residues, conserved in PMs and in other pepsin-like enzymes, that were shown to anchor KNI-764 in a PMIV complex 16 ( Fig. 8b) . However, there is a striking similarity in the binding mode of KNI-10006 to HAP and one of the molecules (designated 1) of an achiral inhibitor bound to PMII (PDB ID 2BJU) 26 ( Fig. 9a ). In the latter structure, two inhibitor molecules are bound to a single PMII molecule, with the second inhibitor molecule (2) oriented in a way that is reminiscent of the binding mode of pepstatin A to HAP. Both the n-pentyl chain of molecule 1 and the 2,6-dimethylphenyloxymethyl moiety of KNI-10006 occupy the so-called flap pocket. The existence of such a pocket was noted before in human renin. 39 In the HAP complex with KNI-10006, this pocket is open and the conformation of the flap is similar to its conformation in the apoenzyme (Fig. 7) . Comparison of KNI-10006 bound to HAP with three crystal structures of aspartic proteases in complex with inhibitors featuring n-pentyl substituents (PDB IDs 2BJU, 2IGX, and 2IGY) 26, 40, 41 allows for the description of the residues comprising this binding pocket in the PM family and for comparison with other aspartic proteases (Fig. 9b) . The flap pocket is predominantly hydrophobic in PMs and other aspartic proteases. However, an insertion of Phe109A in HAP and PMII or Leu109A in PMIV changes the architecture of this pocket and makes it even more hydrophobic in PMs. The conformation of the inserted residue changes in the complexes with different ligands in order to optimize the interactions with the moieties inserted in the pocket. It should be noted, however, that the side chain of Leu112 in pepsin is oriented in such a way that it occupies some of the space taken by residue 109A in PMs, thus contributing to the interactions with the ligand and partially compensating for the absence of the extra residue in the flap pocket (Fig. 9b) . Another important residue, located at the entrance to the flap pocket, is Phe111 in HAP, substituted by threonine in PMII and by leucine in PMIV. These differences between PMs may bear on their specific ligand preferences.
The active site
Similarly to its counterparts in all pepsin-like aspartic proteases, the active site of HAP is located in a large cleft formed by the N-and C-terminal domains of the protein. Whereas the overall architecture of the active site is preserved, a crucial difference in HAP is the replacement of the canonical aspartate from the N-terminal domain 42 by His32. The other functionally important substitutions are found in the flap area, where the commonly conserved Tyr75 and Val/Gly76 residues are replaced in HAP by Ser and Lys, respectively. The conserved pattern of hydrogen bonds, known as the fireman's grip, 43 is found in the active sites of both the apoenzyme and the inhibitor-bound HAP, although the lengths of the individual hydrogen bonds are affected by the larger size of the side chain of His32 (versus Asp32). As discussed below, some structural features of the active site of HAP also differ between the apoenzyme and the complexes with the inhibitors.
The two active sites in the dimeric apoenzyme are practically identical. Each of them contains a Zn ion bound to side chains that belong to both molecules of the dimer. The Zn ion is tetrahedrally coordinated by the side chains of His32 and Asp215 from one HAP monomer, Glu278A from the other monomer, and a water molecule (Fig. 3b) . Glu278A is located in the loop consisting of residues 274-285, which is inserted into the partner active site, leading to the observed opening of the flap. Asojo et al. 15 reported on a crystallographic dimer of PMII in which the loop containing residues 237-247 is docked into the binding cavity of the 2-fold-related monomer. However, the packing of the loop in the active site is not as tight as that in the HAP dimer (see above). The presence of bound Zn in the active site of HAP has a profound effect on the hydrogen-bond interactions. In the active sites of all pepsin-like aspartic proteases, the catalytic residue Asp215 interacts with the neighboring Thr218, 15, 44 and this interaction is important in maintaining the proper protonation state of the catalytic carboxylate. However, no comparable interaction is present in the active site of apo HAP, where the distance between O γ1 of Thr218 and O δ2 of Asp215 is 4.04 Å. The latter atom also coordinates the Zn ion and is involved in hydrogenbonded interactions with two neighboring water molecules. The other active-site residue, His32, also interacts with the Zn ion via its N ɛ2 atom. The imidazole ring of His32 is fixed in suitable orientation by a N δ1 …O γ hydrogen bond with the side chain of Ser35, the latter also being hydrogen bonded to N ɛ1 of Trp39 via a water molecule (Fig.  10a) . Since the flap is in an open position in the apoenzyme, Ser75 and Lys76 are far away from the active site. The side chain hydroxyl of Ser81 is hydrogen bonded to the main chain NH groups of Lys76 and Ala77, whereas the side chain of Lys76 is solvent exposed. The presence of a metal ion in the active sites of aspartic proteases has not been observed before, although some heavy atom derivatives of retroviral proteases, prepared by soaking in very concentrated salts, included a uranyl ion bound to the two aspartates. 45, 46 Although the coordination of the Zn ion in the active site of HAP resembles that observed in the active site of a metalloprotease DppA (D-aminopeptidase; PDB ID 1HI9) 47 (Fig. 10b) , the lack of inhibition by chelating agents such as ethylenediaminetetraacetic acid indicates that HAP does not function as a metalloprotease, 1 at least toward synthetic peptides. Although the structure of HAP in complex with pepstatin A has been determined at a lower resolution, the electron density clearly indicates the presence of the inhibitor in the active site (Fig. 1b) . The overall orientation of the pepstatin A molecule in the active site of HAP is similar to that in the active sites of mammalian aspartic proteases, as well as in PMII and PMIV. 15 The statine hydroxyl group of pepstatin A is positioned between the two catalytic residues and at hydrogen-bonding distances of the N ɛ2 and O δ2 atoms of His32 and Asp215, respectively (Fig. 10c) . The change, upon ligand binding, of the flap conformation from open to closed is accompanied by a dramatic change in the conformation of Trp39 (Fig. 10c) . A flip of the side chain of the corresponding tryptophan residue has also been observed in the liganded structures of PMII 15 and PMIV, 16 as well as of pepsin. 48 Closing of the flap is important for the catalytic mechanism in pepsin-like aspartic proteases. 44 A motion of this segment brings an important residue, Tyr75, closer to the active-site area, generating a network of hydrogen bonds leading to the catalytic aspartates. Since serine occupies an equivalent position in HAP, closing of the flap cannot generate the same effect. Thus, the exact role of the flap in substrate binding or in the catalytic mechanism is still not entirely clear.
A superposition of the structures of pepstatin A complexes of HAP and pepsin (PDB ID 1PSO), based on the C α atoms of the proteins, shows that whereas the residues in the extended active-site area are well superposed, the statine hydroxyls occupy different positions (Fig. 10d) . For clarity of visualization, we subsequently compared the interactions of the statine hydroxyls with the catalytic residues in two structures by superposing the identical parts of the active sites of HAP and pepsin. These parts of the active sites are involved in the catalytic mechanism and include the loop carrying Asp215 and the central part of the inhibitor with its hydroxyl group that occupies the position of the nucleophilic water molecule. As a result of the latter superposition, N ɛ2 of His32 is close to the O δ1 atom of Asp32 in pepsin (Fig. 10e) , thus completing the superposition of all functional groups that are presumably involved in the catalytic mechanism in both enzymes. A comparison of these two superpositions ( Fig. 10d and e) unambiguously indicates that the shift in the position of the statine hydroxyl group in HAP is most likely dictated by the increased dimensions of the histidine side chain at position 32 (versus aspartate). This shift is determined by the distance between O δ1 of Asp32 and N ɛ2 of His32 in the former superposition and roughly corresponds to the distance between C δ2 and N ɛ2 atoms in the ring of a histidine side chain. A different location of the key functional group of HAP leads to a misalignment of the residues in the extended area of the active site in the Nterminal domain of HAP (Fig. 10e) . These differences in the active sites of HAP and pepsin make the similarity in the pattern of hydrogen bonds between the statine OH group and the catalytic residues even more surprising (Fig. 10f) .
In order to compare the active-site structures of the apoenzyme, HAP-KNI-10006, and HAPpepstatin A, we superposed the C α atoms of these three structures (Fig. 10g) . The superposition shows that the positions of the catalytic His32 and Asp215 residues are very similar in all three structures. Also, the orientation of Trp39 in the apoenzyme and that in the HAP-KNI-10006 complex are identical. The two water molecules located between Ser35 and Trp39 in both structures occupy the same sites. The core hydroxyl group of pepstatin A in the HAPpepstatin A complex occupies the position corresponding to the water molecule bound between the side chains of His32 and Asp215 in the HAP-KNI-10006 complex. This latter water molecule is hydrogen bonded to N ɛ2 of His32 and O δ2 of Asp215. By analogy with pepsin-like aspartic proteases, 13 it may be expected that this water molecule is directly involved in the catalytic mechanism of HAP.
As expected from the sequence similarity, the active-site architecture of HAP is similar to other pepsin-like aspartic proteases. However, the situation in the apoenzyme is quite unique because of the presence of the Zn ion. Although this ion most likely originates from the crystallization mother liquor, its presence in the active site indicates that HAP could be sensitive to elevated zinc concentration. The binding mode of pepstatin A in the active site of HAP indicates that His32 and Asp215 are very likely involved in catalysis. As observed in the other pepsin-like aspartic proteases, Ser35, Trp39, and Thr218 may also play a role in the catalytic mechanism of HAP. High-resolution crystal structures are however required to assign the correct role of all these residues in the reaction mechanism.
Conclusions
Although the structure of HAP from P. falciparum exhibits the expected overall similarity to the structure of pepsin-like aspartic proteases, and to PMs in particular, some substantial differences exist as well. The structural data presented for the apoenzyme and two inhibitor complexes can be interpreted to argue against the hypothesis that HAP functions as an unusual serine protease with an aspartic protease fold. However, the available data do not provide an unambiguous answer about the exact nature of the catalytic mechanism of this unusual enzyme. Although the active site of the apoenzyme HAP can bind a Zn ion in a manner reminiscent of metalloproteases, such as D-aminopeptidase DppA, this similarity may be misleading. First, the metal ion is coordinated by two HAP molecules forming a tight dimer, and yet there is no proof, to date, that dimerization is required for the enzymatic activity. Second, the structures of the inhibitor complexes do not contain any metal ion, and, indeed, they cannot be accommodated between the inhibitor and the active-site residues. An additional complication is the fact that both inhibitor complexes (with pepstatin A and KNI-10006) were solved using crystals grown at a pH level well above the range in which the enzyme is active. Thus, the determination of the details of the enzymatic mechanism of HAP will require further studies, both biochemical and structural. However, an observation that parts of the inhibitor bind in a pocket that is unique to PMs but not utilized for inhibitor binding by other aspartic proteases bodes well for the successful development of broad-specificity compounds capable of simultaneous inhibition of HAP and other PMs. Such compounds could be developed into a new class of antimalarial drugs.
Materials and Methods

Expression and purification of HAP
Expression of the recombinant Trx-tHAP fusion protein was conducted according to a method described previously. 6 Cell pellet of 1-l culture was suspended in 50 ml of potassium phosphate buffer, pH 7.5, containing 1× BugBuster™ reagent (Novagen, Madison WI, USA) and 1 μl of Benznase (Novagen), 250 U/μl. The suspension was incubated at room temperature for 40 min with gentle shaking. The sample was then centrifuged at 16,000g for 20 min at 4°C. The supernatant was applied on a HisSelect™ Cartridge (6.4 ml) (Sigma-Aldrich, Oakville, Ontario, Canada); the column was first flushed with washing buffer (50 mM sodium phosphate, 0.3 M NaCl, and 10 mM imidazole, pH 7.5) and then with 10% elution buffer (50 mM sodium phosphate, 0.3 M NaCl, and 250 mM imidazole, pH 7.5), and it was finally eluted with 50% elution buffer. The eluate was concentrated in 50 mM sodium phosphate buffer, pH 7.5, containing 0.2% Chaps in an Ultracel YM50 Centricon (Millipore, Billerica, USA) and further purified by gel filtration using a Superose™ 12 10/300 GL column (GE Healthcare, Uppsala, Sweden) equilibrated with 50 mM sodium phosphate buffer, pH 7.5, containing 150 mM NaCI and 0.2% Chaps to obtain pure Trx-tHAP fusion protein. Two peaks were observed on the chromatogram. Fractions from peak 2 were collected and washed with 50 mM sodium phosphate buffer, pH 7.5, containing 0.2% Chaps. Subsequently, the Trx-tHAP protein was activated with enteropeptidase (Sigma, St. Louis, MO) (EK/TrxtHAP = 1:25) in 50 mM Mes buffer, pH 6.5, containing 0.2% Chaps at 37°C for 2 days. After checking the initial purity of the protein sample by SDS-PAGE, the activated mtHAP was purified by washing with 50 mM Mes buffer (pH 6.5), in an Ultracel YM30 Centricon (Millipore, Billerica, USA) to remove the cleaved prosegment and thioredoxin, yielding mature tHAP (mtHAP). mtHAP was further purified by gel filtration with a Superose™ 12 10/300 GL column equilibrated with 50 mM Mes buffer, pH 6.5, containing 150 mM NaCI and 0.2% Chaps. The fractions from the second major peak were washed and concentrated in 50 mM MES buffer, pH 6.5, to about 10 mg/ml concentration, then frozen in liquid nitrogen and stored at -80°C. As shown previously 6 and again verified by mass spectrometry (data not shown), protein purified by this procedure consists of 332 amino acids. HAP used in this study contains four additional residues on its N-terminus that originate from the propeptide and are not present in the native protein directly isolated from P. falciparum. (1:1 protein/inhibitor molar ratio). The sample was subsequently incubated for 2 h and centrifuged. Several crystallization screens were set up using the sitting-drop vapor-diffusion method at 293 K, and a few conditions produced small needles. The conditions were optimized using the hanging-drop vapor-diffusion method at 293 K. Two types of crystals (type I and type II) were grown 
Data collection
X-ray diffraction data for type I and type III crystals were collected using a MAR300CCD detector and a wavelength of 0.9999 Å at the SER-CAT (Southeast Regional Collaborative Access Team) 22-ID beamline at the Advanced Photon Source (Argonne National Laboratory, Argonne, IL). Data for a type II crystal were collected using Cu Kα radiation generated by a Rigaku H3R X-ray source and a MAR345dtb detector. All data were collected at 100 K using, as cryoprotectant, 20% (v/v) methyl-2,4-pentanediol for type I crystals and 20% ethylene glycol (v/v) for type II and type III crystals added to reservoir solution. Type I crystals are tetragonal in space group P4 1 2 1 2, type II crystals are trigonal in space group P3 2 21, and type III crystals are tetragonal in space group I4 1 22. All data sets were indexed and integrated using XDS. 49 The data were converted to structure factors with modules F2MTZ and CAD of CCP4. 50 Structure solution and refinement HAP has a high level of sequence identity with PMII (60.6%) and PMIV (61.8%). Several crystal structures of both PMs are available in the PDB, providing a wide choice of starting models for molecular replacement. The structures of the apoenzyme and of its complexes with pepstatin A and KNI-10006 were solved by molecular replacement using MrBUMP, 51 MOLREP, 52 and PHASER. 53 The Matthews coefficient 54 indicated the likely presence of two molecules in the asymmetric unit of type I crystal. The automated search performed with MrBUMP identified the B-chain of PMIV (PDB ID 2ANL) as the best search model. The final molecular replacement procedures utilized directly the programs MOLREP 52 and PHASER. 53 The preliminary model was refined with REFMAC5 55 and rebuilt with COOT. 56 Very tight NCS restraints were used in the initial stages of refinement, but slowly the restraints were released as the model was becoming more complete; medium NCS restraints were applied for the final refinement cycles. Zn ions and water molecules were progressively introduced at peaks of electron density higher than 3σ in (F o − F c )α c σ a -weighted maps while monitoring the decrease of R free . Proper hydrogen bonding was required for placement of all solvent molecules. PROCHECK 10 was used to monitor the stereochemistry of the protein model. Although the type I crystals were grown using HAP incubated in the presence of pepstatin A, careful analysis of the difference electron density map did not show the presence of the inhibitor in either of the active sites of the dimer. Seven residues (−5 to −1 and 327 and 328) are missing from each subunit in the final model of the apoenzyme; these residues could not be built because of lack of features in the electron density map. All other residues are well defined in the map.
The crystal structure of HAP in complex with pepstatin A was determined using data obtained from a type II crystal, which contained only one protein molecule in the asymmetric unit. Automated search by MrBUMP, using the A-chain of PMII (PDB ID 1SME) as the probe, correctly placed the model in the asymmetric unit. After the first cycle of refinement in REFMAC5, the (F o − F c )α c electron density map indicated the presence of pepstatin A in the active site (Fig. 1b) . After modeling the inhibitor, iterative cycles of model refinement with REFMAC5 and model building in the electron density maps using COOT were carried out. The overall anisotropy was modeled with translation-libration-screw (TLS) parameters by dividing the protein molecule into two TLS groups, comprising residues 2-210 and 211-326. PROCHECK was used to monitor the stereochemistry of the model. Nine residues (−5 to 1 and 327 and 328) of the HAP molecule could not be modeled in the electron density map.
Solvent content analysis showed that the crystals of HAP in complex with KNI-10006 (type III) contain four protein molecules in the asymmetric unit. The structure of this complex was determined by molecular replacement using the coordinates of the protein from its pepstatin complex. Automated search by PHASER revealed the correct placement of the first two molecules in the asymmetric unit. These two molecules, which did not form a dimer similar to that observed in the apoenzyme structure, were subsequently used to find the correct orientation of the two remaining molecules in the asymmetric unit. Initially, a few cycles of refinement using REFMAC5 and rebuilding using COOT were performed for the protein only. Subsequent analysis of the (F o − F c )α c electron density map (Fig. 1b) indicated the presence of the KNI-10006 inhibitors in the active site of each of the four monomers. After inhibitor modeling, iterative cycles of refinement in REFMAC5 and model building in the electron density maps using COOT were carried out. Very tight NCS restraints were used during all refinement cycles. The overall anisotropy was modeled with TLS parameters by dividing each molecule into two TLS groups, comprising residues 0-194 and 195-327. In the final model, six residues (−5 to − 1 and 328) are missing from all four molecules because of lack of features in the electron density map. The refinement statistics for all three structures are presented in Table 1 . The structures were analyzed using PROCHECK 10 and COOT. 56 Structural superpositions were performed with SSM 57 and ALIGN, 17 and the figures were generated with PYMOL. 58 
PDB accession numbers
Atomic coordinates and structure factors have been deposited in the PDB with code 3FNS for the HAP apoenzyme, code 3FNT for the complex with pepstatin A, and code 3FNU for the complex with KNI-10006.
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